Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster immunogenicity study of new versus current GSK DTPa-HBV-IPV/Hib formulation in toddlers
2012-002428-34Phase 4
- Sponsor
- GSK
- Start
- Apr 2015
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, double-blind trial of pertussis filamentous haemagglutinin and diphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccine in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by GSK. Primary endpoint: Seroprotection status in the DTPa-HBV-IPV/Hib groups.
02
Drugs
pertussis filamentous haemagglutinindiphtheria toxoid + tetanus toxoid + acellular pertussis + hepatitis B recombinant + inactivated poliovirus vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2012-002428-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002428-34.